BioCentury | Jun 27, 2020
Product Development

BARDA no longer funding immunomodulators as support for the therapeutic class to treat COVID-19 grows

...Forxiga dapagliflozin from AstraZeneca plc (LSE:AZN; NYSE:AZN) Volibris, approved for pulmonary hypertension, is a selective endothelin A receptor...
BioCentury | Jan 11, 2020
Company News

Chinook to spin AbbVie castoff into personalized kidney disease candidate

...of atrasentan from AbbVie. The biotech plans to put its precision medicine spin on the endothelin A receptor...
BioCentury | Apr 10, 2019
Company News

Gilead cuts cardiopulmonary sales reps

...Inc. (NASDAQ:GILD) spokesperson told BioCentury (see "O'Day's Expansive Task at Gilead" ). Letairis, a selective endothelin A receptor...
...Gilead gained $1.31 to $67.40 on Wednesday. Chris Lieu, Staff Writer Letairis, Volibris, ambrisentan Ranexa, ranolazine (latixa) Gilead Sciences Inc. Endothelin A receptor...
BioCentury | Jul 13, 2018
Financial News

Idorsia raises $511.9M in dual offerings

...YE18, it plans to report data from a Japanese Phase III trial of clazosentan, an endothelin A receptor...
...lost another CHF0.14 to CHF25.52 on July 12. Idorsia Ltd. (SIX:IDIA), Allschwil, Switzerland Jennie Walters Pivlaz, clazosentan Idorsia Ltd. Endothelin A receptor...
BioCentury | Jul 12, 2018
Financial News

Idorsia raises $511.9M in dual offerings

...YE18, it plans to report data from a Japanese Phase III trial of clazosentan, an endothelin A receptor...
BioCentury | Sep 8, 2017
Clinical News

FDA approves Tracleer for pediatric PAH

...& Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Tracleer bosentan Business: Cardiovascular Mary Romeo Tracleer Actelion Ltd. Idorsia Ltd. Johnson & Johnson Endothelin A receptor Endothelin...
BioCentury | Sep 6, 2017
Company News

FDA approves Tracleer for pediatric PAH

...stage assets (see BioCentury Extra, Jan. 26 and June 16) . Mary Romeo Tracleer Actelion Ltd. Idorsia Ltd. Johnson & Johnson Endothelin A receptor Endothelin...
BioCentury | Jun 16, 2017
Financial News

Actelion spinout Idorsia rises in first trading day

...hypertension; ACT-541468 , a dual orexin receptor antagonist (DORA) to treat insomnia; clazosentan , an endothelin A receptor...
BioCentury | Jun 9, 2017
Financial News

Actelion spinout Idorsia to list next week

...ACT-541468, a dual orexin receptor antagonist (DORA) in development to treat insomnia; clazosentan , an endothelin A receptor...
BioCentury | Feb 4, 2017
Strategy

Actelion, take two

...S1PR1 ; S1P1 ; EDG1) modulator to treat systemic lupus erythematosus (SLE). Clazosentan is an endothelin A receptor...
Items per page:
1 - 10 of 399